biopharmaceutical (chronic hepatitis infections) · United States | Hepatitis D and hepatitis B testing and treatment claims for a US biopharmaceutical company's franchise: 113,235,341 patient level rows covering 7,144,993 distinct patients, with ages, birth years, payer details and provider identities; Prescription claims for the company's hepatitis D product with patient identifiers, prescriber NPI numbers and payer details | [NOT PAID — EXPOSED]
🏴☠️ N0n has just published a new victim : Vir Biotechnology, Inc.
About this summary. This is a short excerpt from the description that ransomware.live published with its article. Cyber Security News did not report or verify the underlying story. Read the original: https://www.ransomware.live/id/VmlyIEJpb3RlY2hub2xvZ3ksIEluYy5ATjBu

Source attribution: headline and facts are from ransomware.live (ransomware.live). Summary method: excerpt of the source description. See our source attribution policy.






